Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.

Laura RozenblumCaroline HouillierAmandine BaptisteCarole SoussainVéronique EdelinePhilippe NaggaraMarine SoretValérie Causse-LemercierLise WillemsSylvain ChoquetRenata UrsuDamien GalanaudLisa BelinKhê Hoang-XuanAurélie Kas

Published in: Neuro-oncology (2024)

LOCALYZE, NCT03582254, ancillary of phase III clinical trial BLOCAGE01, NCT02313389 (Registered July 10, 2018-retrospectively registered) https://clinicaltrials.gov/ct2/show/NCT03582254?term=LOCALYZE&draw=2&rank=1.

Keyphrases

phase iii
clinical trial
open label
positron emission tomography
pet ct
phase ii
computed tomography
double blind
pet imaging
study protocol
placebo controlled
preterm infants
image quality
dual energy
cerebrospinal fluid
gestational age
randomized controlled trial
combination therapy